Core Insights - Elevance has appointed Amy Schulman, a former Pfizer executive, to its board of directors as part of its strategy to enhance its pharmacy services [3][8] - Schulman brings extensive experience in the healthcare sector, including her roles at Pfizer and her current position at Polaris Partners [4][5] - The addition of Schulman is expected to support Elevance's growth in its Carelon health services division, which includes its pharmacy benefit manager, CarelonRx [7][8] Company Strategy - Elevance is focusing on building its board with experienced professionals from the pharmaceutical industry to strengthen its service offerings [3][8] - The company aims to expand its pharmacy services, particularly through the Carelon division, which was rebranded in 2022 [7] Executive Background - Amy Schulman has held senior roles at Pfizer, including general counsel and president of Pfizer Nutrition, and has significant governance experience [5][6] - Her expertise in the intersection of science, technology, and patient care is seen as a valuable asset for Elevance [8]